RAND report shows benefit of investment in future health outcomes for adults with Down syndrome
10/1/2024 | For immediate release | Contact: Kate O’Neill ([email protected]) Investment in Alzheimer’s Research Today Will Yield Health Benefits for the Next Generation of Adults With Down Syndrome, New Report […]
Updates from AAIC: Down syndrome community boosted by FDA confirmation of label and new anti-amyloid clinical trial
Information revealed at the 2024 AAIC conference on the ACTC-DS-led study in DS-associated Alzheimer’s disease with Lilly’s anti-amyloid drug Kisunla. At the 2024 Alzheimer’s Association International Conference in Philadelphia this […]
FDA issues approval for new Alzheimer’s drug Kisunla; Down syndrome community is optimistic
FDA issues approval for Kisunla, new Alzheimer’s drug; Down syndrome community optimistic On Tuesday, July 2, the U.S. Food and Drug Administration (FDA) announced the approval of Kisunla (donanemab), an […]
Down syndrome population will see a clinical trial of new Alzheimer’s drug
Major pharmaceutical company announces Down syndrome population will see a clinical trial of new Alzheimer’s drug People with Down syndrome will be invited to participate in a clinical trial of […]
Down syndrome collaborators now published in Alzheimer’s and Dementia
“Adapting prescribing criteria for amyloid‐targeted antibodies for adults with Down syndrome” published in the journal of the Alzheimer’s Association Drawing attention to policies currently preventing people with intellectual disabilities from […]
LuMind IDSC statement on FDA Advisory Committee for promising Alzheimer’s drug, donanemab
LuMind IDSC is encouraged by today’s news that the U.S. Food and Drug Administration (FDA) is requesting more time and information before making a decision on the status of donanemab, […]
Study: Medicare, Medicaid, and Dual Enrollment for Adults with Intellectual and Developmental Disabilities.
Medicare, Medicaid and Dual Enrollment for Adults with IDD Boston University School of Public Health recently published an article in Health Services Research Journal entitled Medicare, Medicaid, and Dual Enrollment […]
Reuters Article: Barriers to Latest Alzheimer’s Treatments for Down Syndrome Community
Hampus Hillerstrom, CEO of LuMind IDSC Foundation and father to a child with Down syndrome, knows about the barriers people with Down syndrome face in accessing the latest Alzheimer’s treatments. […]
Boston Globe OpEd People with Down Syndrome Now Left Out of Treatment
LuMind IDSC and The Arc of Northeast collaborated on an OpEd that was recently published in The Boston Globe. Authors Hampus Hillerstrom and Jo Ann Simons are leaders of their […]
Study: Use of Medicaid by Adults with Down Syndrome
Medicaid Enrollment and Service Use Among Adults with Down Syndrome September 16, 2023 In a recently published study in the Journal of American Medical Association (JAMA) Health Studies it was […]